Altheos begins patient dosing in glaucoma drug trial
Altheos has announced the dosing of first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907.
ATS907 is a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and ocular hypertension.
The randomized controlled investigator masked dose-ranging safety and efficacy first-in-human study enrolled subjects with primary open angle glaucoma and/or ocular hypertension.
The trial employs a two-stage adaptive design to examine a number of different doses of ATS907 ophthalmic formulation and to provide preliminary information on safety, tolerability and efficacy following 28 days of administration.
Altheos chief medical officer Barbara Wirostko said the drug showed excellent ocular surface penetration, and is rapidly converted into a more active form in the anterior chamber after topical dosing.
The company has raised an additional $12.5m in its Series A financing from the existing and additional investors to advance the drug candidate through Phase 2 clinical and Phase 3 trials.
Altheos anticipates to commence the second stage of this trial, a comparison of ATS907 and latanoprost (a prostaglandin analogue).
Related Insight
Suppliers Directory
Investigator Location Services - Instant Access to Experienced Clinical Investigators
Investigator Location Services, Inc. (ILS), is the largest study broker with instant access to over 20,000 experienced clinical research investigators in the US and Canada in all medical specialties and practice settings. Our site provides a center for all clinical research and clinical trial personnel solutions.
Contract Research & Services > Clinical Trials > Suppliers
Cancer Research Technology (CRT) - Advancing Discoveries to Beat Cancer
Cancer Research Technology Ltd (CRT) is the cancer-focused technology development and commercialisation arm of Cancer Research UK, the world's largest cancer charity.
Contract Research & Services > Clinical Trials > Suppliers
Biotec Services International Limited - Pharmaceutical Outsourcing Services
Established in 1997, Biotec is a privately owned leading Pharmaceutical services company specialising in cold chain packaging, storage and logistics services.
Contract Research & Services > Clinical Trials > Suppliers
Centrical Global Limited - Global Clinical Trial Feasibility
Centrical specialises in comprehensive, streamlined, industry-leading global clinical trial feasibility for pharmaceutical and biotechnology companies.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
ILS Client List
Published by Investigator Location Services
Contract Research & Services > Clinical Trials > White Papers
Management and Analysis of Biomarker Data
Published by Exploristics
Contract Research & Services > Clinical Trials > White Papers
Protecting Sensitive Information in Life Sciences Organisations
Published by Brainloop
Contract Research & Services > Clinical Trials > White Papers
Synevo Central Lab - An Interview with Tomasz Anyszek, MD, PhD, Managing Director
Published by Synevo Central Lab
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.